Safety Shot (NASDAQ: SHOT) today announced its entry into an agreement with mixed martial arts (“MMA”) superstar Jorge Masvidal’s Gamebred Bareknuckle MMA, the world’s first bareknuckle MMA promotion. Over the next year, Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, will be the ring sponsor for 12 Gamebred Bareknuckle matches. “Jorge is a superstar in the MMA world with a huge following and his Gamebred Bareknuckle fight promotion has garnered a fast growing following with millions of people viewing matches online and live audiences cheering at venues across the country,” said Safety Shot’s CEO Brian John. “We’re excited to sponsor Gamebred and to make its fans aware of the health benefits of our drink.”
To view the full press release, visit https://ibn.fm/e6nWE
About Safety Shot Holdings Inc.
Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. The company plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://jupiterwellness.com/email-alerts/.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights,…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE…
HealthLynked (OTCQB: HLYK) has completed a reverse stock split as part of its strategy to…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of…
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data…
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an…